Private equity firm Ampersand Capital Partners announced the acquisition of Biologos LLC, a full-service manufacturer of custom and standard cell culture media, reagents, buffers, enzymes, and sera. This partnership with Ampersand will include investments for expanding Biologos’ capabilities, product offerings, and geographic reach to support its global cell and gene therapy, biopharmaceutical, tissue processing, and animal health customers.
Founded in 1976, Biologos has become a leader in providing custom and standard products spanning cell culture media, reagents, enzymes, salts/buffers, and sera. Many of these products have customized container, fill, and packaging solutions. Biologos operates from a brand new, 32,000-square-foot cGMP facility just outside Chicago, IL.
As part of the deal, Frank Witney, an industry veteran and Ampersand Operating Partner, has been named Chairman of Biologos. Eric Lev and Mario Reto of Ampersand have also been appointed as new Board Members.
KEY QUOTES:
“This is an exciting time at Biologos as we have experienced impressive growth thanks to our team’s ability to provide high-quality standard and custom biologics solutions for our customers. Ampersand’s deep industry expertise, broad network, and capital resources will enable Biologos to accelerate its growth strategy through the development of new products and its expansion into new markets.”
– Biologos CEO Tony Bazarko
“The investment in Biologos aligns well with Ampersand’s strategy of supporting growth-oriented life science organizations with a history of product innovation and customer excellence. Under Tony’s leadership, we are confident in the team’s ability to continue its strong momentum and look forward to partnering together on this growth journey.”
– Eric Lev
